Saving lives through our platform technology, making cost-effective bio industrials and therapeutics available for everyone, everywhere.

Research & Technology

We leverage innovative vaccine technology to ensure affordable and efficient products.

Innovative Platform Technology

BROAD-SPECTRUM APPLICATIONS

Gefjon Pharma’s platform technology is built on a genetically modified, hyper-productive, and patentable bacterial strain, enabling efficient and cost-effective protein expression. Combined with an optimized extraction and production process, this innovation supports a wide range of applications in both veterinary and human medicine.

E. coli vaccine for poultry

SEVEN CLINCAL TRIALS

Our initial product is an innovative broad-spectrum E. coli vaccine for poultry, developed using outer membrane vesicles. With a validated proof of concept for both the vaccine and an aerosol delivery system, it targets a leading cause of mortality and infection in poultry. By reducing reliance on antimicrobials, it improves animal welfare, decreases CO₂ emissions and food waste, and increases revenue opportunities for producers.

Research & Development

ONGOING RESEARCH PROJECTS

Gefjon Pharma is diligently exploring new applications for its platform technology through collaborative research and development projects with the University of Copenhagen. By consistently driving innovation, we aim to unlock new solutions in both veterinary and human medicine.

Our OMV-platform technology revolutionizes pharmaceutical and bio-industrial production

Gefjon Pharma has developed a groundbreaking OMV-based platform technology for scalable, low-cost production of pharmaceuticals and bio-industrial products.

By simplifying manufacturing, our platform makes advanced biologics commercially viable in markets where traditional production is often too expensive.

Our lead asset: EVax/02

EVax/02 is a next-generation OMV-based E. coli vaccine for poultry and the first product built on Gefjon Pharma’s OMV platform. Developed for industrial poultry production, it targets one of the sector’s most damaging bacterial diseases.

The vaccine is aerosol-administered, non-live, broadly protective and cost-competitive, demonstrating how our platform translates into scalable products for real market needs.

Our Leadership Team

With over 75 years of combined experience in research, development, pharmaceutical production, business, and business development, our team brings diverse expertise and strong foundations for building successful companies.

Anders Miki Bojesen

Chief Scientific Officer

Co-founder

Fabio Antenucci

Chief Technology Officer

Co-founder

Thomas Buthler

Chief Operations & Quality Officer

Co-founder

Torben Hald

Chief Executive Officer

Co-founder

Advisory Board

Gefjon Pharma benefits from an experienced advisory board.

Carl-Åke Carlsson

DelsiTech

Klaus-Peter Behr

ABICS GmbH

Anja E. H. Holm

CentralVetPharma

Lasse Pedersen

Ellab A/S

Rasmus Hansen

Vetgruppen

Skærmbillede 2026-02-17 kl. 14.48_edited.jpg

Dr. Neta Kela

UCPH Lighthouse

Louise Lyhne

Lyhne Life

Partners

Gefjon Pharma has been recognized and supported by several respected institutions, highlighting the significance and potential impact of our work. We have partnered with industry leaders and expert research collaborators.